lineage	aa_name	mutation_effects	function_category	mutation_effect (1st iteration)	source	citation	pokay_link	ontology_terms	status
B.1.1.7	N501Y	increased affinity for hACE2, "associated with fast growing lineages", within the six key residues in the receptor binding domain (RBD), estimated to cause an increase of between 40% and 70% in transmissibility, Experimentally, ACE2 binding affinity increased 0.24 fold, Calculated disassociation constant for this variant is nearly four fold lower than wild type (455 pM vs 1600pM) #Variant within the six key residues in the receptor binding domain (RBD), Independently reported in UK, Australia (same origin as UK), and South Africa (independent origin). # In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	ACE2 receptor binding affinity increase | Convalescent plasma escape | Homoplasy | Monoclonal antibody serial passage escape | Vaccine neutralization efficacy | Variant linear antibody epitope effect	Experimentally, ACE2 binding affinity increased 0.24 fold |  Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus. | Variant within the six key residues in the receptor binding domain (RBD). | In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613. | In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed. | Decrease in potency was  observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	https://doi.org/10.1016/j.cell.2020.08.012 | https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2 | https://www.mdpi.com/2076-0817/10/2/184/htm | https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2 | https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  | https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1 	Starr et al. (2020) | Shen et al. (2021) | Flores-Alanis et al. (2021) | Wang et al. (2021) | Wang et al. (2021)  | Rees-Spear et al. (2021) 	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_homoplasy.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_vaccine_neutralization_efficacy.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt 	| Receptor Binding: http://purl.obolibrary.org/obo/NCIT_C40536 |     Epitope: http://purl.obolibrary.org/obo/CHEBI_53000  has related synonym: epitope function, antigenic determinant, epitope role |  homoplasy: http://purl.obolibrary.org/obo/HOM_0000002 in homoplasy relationship with: http://purl.obolibrary.org/obo/RO_HOM0000002  	complete for now: Added one function for each category. Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.1.7	A570D							Convalescent Plasma: http://purl.obolibrary.org/obo/NCIT_C173750 COVID-19 Convalescent Plasma: http://purl.obolibrary.org/obo/NCIT_C171633    (but I think these won't suit us)  Closest term is 'Trafficking Protein Gene' : http://purl.obolibrary.org/obo/NCIT_C26006  	In Pokay, its function so far is only available in combination with other mutations. 
B.1.1.7	P681H	May help infected cells create new spike proteins more efficiently https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117   Recurrent deletions in vairous lineages related to several RBD mutations.  one of 4 residues comprising the insertion that creates a furin cleavage site between S1 and S2 in spike. The S1/S2 furin cleavage site of SARS-CoV-2 is not found in closely related coronaviruses and has been shown to promote entry into respiratory epithelial cells and transmission in animal models.  Pokay: "adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic"							In Pokay, its function so far is only available in combination with other mutations. 
B.1.1.7	T716I	"Not in a major wildtype epitope, mutant increases PIWAS epitope score from 0.69% to 2.3% # Found in B.1.1.7 lineage, but assumed to not play a major role in antigenicity." (Pokay) # Observed first in a single tiger (cohort of 5), potential adaptation. (pokay) 	Antibody epitope effect | Anthropozoonotic events	Mutant increase Protein-based Immunome Wide Association Studies (PIWAS ) epitope score from 0.69% to 2.3% but assumed to not play a major role in antigenicity. | Observed first in a single tiger (cohort of 5), potential adaptation.	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1 | https://dx.doi.org/10.1128/mBio.02220-20 	Haynes et al. (2021) | McAloose et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_anthropozoonotic_events.txt 	| | maybe we can use 'zoonosis' : http://purl.obolibrary.org/obo/MONDO_0025481 An infectious disease of non-human animals that may be transmitted to humans or may be transmitted from humans to non-human animals, caused by a pathogen (an infectious agent, including bacteria, viruses, parasites, prions, etc)  zoonosis: http://purl.obolibrary.org/obo/IDO_0000568 An infectious disease that has as its physical basis an infectious disorder composed of infectious agents that have a zoonotic disposition.	complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.1.7	S982A	"Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score # Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity." (Pokay) # The neutralizing activity of 6/20 convalescent sera was significantly lower against this single variant pseudotyped virus model, showing similar patterns to the pseudotyped virus model of B.1.1.7.	Antibody epitope effect | Convalescent plasma escape 	Mutant has no significant effect on PIWAS epitope score and assumed to not play a major role in antigenicity. | The neutralizing activity of 6/20 convalescent sera was significantly lower against this single variant pseudotyped virus model, showing similar patterns to the pseudotyped virus model of B.1.1.7.	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1  | https://www.nature.com/articles/s41586-021-03398-2 	Haynes et al. (2021) | Wang et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt  		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.1.7	D1118H	"Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score # Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity." (pokay)	Variant linear antibody epitope effect 	Mutant has no significant effect on PIWAS epitope score and assumed to not play a major role in antigenicity.	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1 	Haynes et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.1.7	HV 69-70 deletion H69, V70 del	evasion to the human immune response but has also occurred a number of times in association with other receptor-binding domain (RBD) changes.  Has been detected in immunocompromised patients.  Enhances viral infectivity. "Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma" (Pokay) "# The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] # Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7." (Pokay) -Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI). # Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma # Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*. 	Antibody epitope effect | Convalescent plasma escape | Immunosuppression variant emergence	Reduces neutralization by structurally unmapped mAb COVA1-21. | Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma ;  Neutralization activity of almost all Moderna Phase 1 sera tested actually increased. | The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change (with which it is found in lineage B.1.1.7), possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.   	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1 | https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1  ; https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2 | https://doi.org/10.1101/2020.12.14.422555 	Rees-Spear et al. (2021) |  Kemp et al. (2020) ; Shen et al. (2021) | Kemp et al. (2020) 	https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt  ; https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_immunosuppression_variant_emergence.txt 		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation. (semicolon is used to seperate functions, when single category has multiple functions)
B.1.1.7	Y144 deletion	# Alter the shape of the spike and may help it evade some antibodies. https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117  # Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) # Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.  # Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1 # Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i"  # Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i"  # Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i"  # Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition)  "# McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"  (Pokay)  							In Pokay, its function so far is only available in combination with other mutations. 
B.1.1.7	R52I	ORF8: There is a small amount of data about variants affecting ORF8, a viral accessory protein which may be involved in immune evasion by downregulation of MHC class I. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf							Not in Pokay
B.1.1.7	Q27stop	truncates the ORF8 protein or renders it inactive and thus allows further downstream mutations to accrue.							Not in Pokay
B.1.1.7	Y73C	#Crystal structure of ORF8 shows two dimerization interfaces unique to SARS-CoV-2 genealogy. The R52I and Y73C mutations are localized at these interaction interfaces. In wild type strain, R52 forms H-bond contact with I121 from another protomer. Y73 forms part of crucial 73YIDI76 non-covalent ORF8 dimer interaction interface, unique to SARS-CoV-2. Presence of these interfaces enables ORF8 to form large scale assemblies, possibly aiding SARS-CoV-2 to evade and modulate host immune responses https://www.biorxiv.org/content/10.1101/2021.01.01.425028v1.full 							Not in Pokay
B.1.1.7	D3L	# A noncanonical subgenomic RNA which could represent ORF9b is significantly enriched (~16x) in B.1.1.7 SARS-CoV-2 infections,  potentially as a result of a triple nucleotide mutation leading to amino acid substitution D3L in nucleocapsid in this lineage which increases complementarity with the genomic leader sequence.  # At the epitope level, the D3L mutation reduces PIWAS signal in 1.5% of COVID patients (outliers reduce from 2.1% in wild type to 0.5% in mutant). # In 3 of these patients (0.5% of the population), that alteration represents the strongest antigen signal and substantially reduces the PIWAS antigen score. # In the B1.1.7 lineage this is largely counteracted by the S235F mutation, which increases epitope and antigen scores significantly in two individuals, for a net neutral effect at the population level. 	Subgenomic RNA expression | Variant linear antibody epitope effect	 A noncanonical subgenomic RNA which could represent ORF9b is significantly enriched (~16x) in B.1.1.7, potentially as a result of a triple nucleotide mutation leading to amino acid substitution D3L in nucleocapsid which increases complementarity with the genomic leader sequence. | At the epitope level, the D3L mutation reduces PIWAS signal in 1.5% of COVID patients  ; In 0.5% of the population, that alteration represents the strongest antigen signal and substantially reduces the PIWAS antigen score ; In the B1.1.7 lineage this is largely counteracted by the S235F mutation, which increases epitope and antigen scores significantly in two individuals, for a net neutral effect at the population level.	https://www.biorxiv.org/content/10.1101/2021.03.02.433156v1  | https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1 ; https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1  ; https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1 	Parker et al. (2021)  |Haynes et al. (2021) ; Haynes et al. (2021) ; Haynes et al. (2021) 	https://github.com/nodrogluap/pokay/blob/master/data/N_subgenomic_RNA_expression | https://github.com/nodrogluap/pokay/blob/master/data/N_variant_linear_antibody_epitope_effects.txt ; https://github.com/nodrogluap/pokay/blob/master/data/N_variant_linear_antibody_epitope_effects.txt ; https://github.com/nodrogluap/pokay/blob/master/data/N_variant_linear_antibody_epitope_effects.txt 		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.1.7	S235F	# Substantially increases epitope and antigen scores in 2 of 579 individuals (should increase immune response). # In the B1.1.7 lineage this is largely counteracted by the D3L mutation, which decreases PIWAS signal significantly in 1.5% of COVID patients, for a net neutral effect at the population level.	Variant linear antibody epitope effect	Substantial increase in epitope and antigen score; In the B1.1.7 lineage this is largely counteracted by the D3L mutation, which decreases PIWAS signal significantly in 1.5% of COVID patients, for a net neutral effect at the population level.	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1	Haynes et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/N_variant_linear_antibody_epitope_effects.txt		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.1.7	T1001I	Not in Pokay							Not in Pokay
B.1.1.7	A1708D	Not in Pokay							Not in Pokay
B.1.1.7	I2230T	Not in Pokay							Not in Pokay
B.1.1.7	SGF 3675-3677 deletion	Not in Pokay							Not in Pokay
B.1.1.7		Not in Pokay							Not in Pokay
B.1.1.7		Not in Pokay							Not in Pokay
B.1.1.7		Not in Pokay							Not in Pokay
B.1.1.7		Not in Pokay							Not in Pokay
B.1.1.7		Not in Pokay							Not in Pokay
B.1.1.7		Not in Pokay							Not in Pokay
B.1.351	T265I	Not in Pokay							Not in Pokay
B.1.351	K1655N	Not in Pokay							Not in Pokay
B.1.351	H2799Y	Not in Pokay							Not in Pokay
B.1.351	S2900L	Not in Pokay							Not in Pokay
B.1.351	K3353R	Not in Pokay							Not in Pokay
B.1.351	D4527Y	Not in Pokay							Not in Pokay
B.1.351	T5912I	Not in Pokay							Not in Pokay
B.1.351	L18F	"# Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i", but no effect on other mAbs within that supersite # McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475" (Pokay) contributor to convalescent plasma escape (Pokay)  # Likely play a role in protein folding and immune evasion and may have implications in viral virulence and vaccine design. https://www.medrxiv.org/content/10.1101/2021.01.29.21250757v1.full-text 							In Pokay, its function so far is only available in combination with other mutations. 
B.1.351	D80A	contributor to convalescent plasma escape (Pokay)							In Pokay, its function so far is only available in combination with other mutations. 
B.1.351	D215G	contributor to convalescent plasma escape (Pokay)							In Pokay, its function so far is only available in combination with other mutations. 
B.1.351	L242H	# Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  # 501Y.V2 ("South African") lineage background variant R246I to disrupt paratope binding. # Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1 (Pokay)							
B.1.351	L242_244L deletion; L242del,L243del,L244del	contributor to convalescent plasma escape (Pokay)  # Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  # 501Y.V2 ("South African") lineage background variant R246I to disrupt paratope binding. # Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1 (Pokay)							
B.1.351	R246I	# Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, this residue is known to be key for CDR-H1 mediated # interactions. May work synergistically with 501Y.V2 ("South African") lineage background deletion 242del,243del,244del to disrupt paratope binding # via steric clash with residue R102. # Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1  (Pokay)							Can't find in Pokay
B.1.351	K417N	# Helps the virus bind more tightly to human cells.  at a key residue in the RBD; contributor to convalescent plasma escape (Pokay); "#Experimentally, Spike gene expression increased 0.1 fold #Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012" (Pokay)  The spike RBD is the main target of neutralizing antibodies (NAbs) elicited during SARS- CoV-2 infection37. Class 1 antibodies have a VH3-53 restricted mode of recognition centred around spike residue K417. The K417N mutation abolish key interactions with class 1 NAbs, and likely contributes toward immune evasion at this site. # Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM). # In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361.  # Escape mutation against monoclonal antibody LY-CoV016 # Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 # In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660 # Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	ACE2 receptor binding affinity increase | Convalescent plasma escape | Gene expression increase | Monoclonal antibody serial passage escape	 Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface. | In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361. | Experimentally, Spike gene expression increased 0.1 fold | Escape mutation against monoclonal antibody LY-CoV016 ; In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660.  	 https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2 |  https://www.nature.com/articles/s41591-021-01294-w  | https://doi.org/10.1016/j.cell.2020.08.012  | https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 ; https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  	Tian et al. (2021) | Chen et al. (2021) | Starr et al. (2020) | Starr et al. (2021) ; Wang et al. (2021) 	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt |  https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_gene_expression_increase.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt 		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation. (semicolon is used to seperate functions, when single category has multiple functions)
B.1.351	E484K	can "escape several mAbs (including C121, C144, REGN10933, REGN10934) and some convalescent sera", at a key residue in the RBD; "substantially increases the amount of serum antibody needed to prevent infection of cells"; contributor to convalescent plasma escape; "# Ablates binding by class 2 mAbs such as C144 that do not directly interfere with ACE2 binding,  # BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  # show pronounced increase in binding to the variant.  # Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"  (Pokay) #The mutation is in the spike protein and appears to have an impact on the body’s immune response and, possibly, vaccine efficacy. # Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM). # This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity 	ACE2 receptor binding affinity increase | Convalescent plasma escape	Reported moderate increase in affinity compared to wild-type RBD on the cell surface.| Mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity. 	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2  | https://www.biorxiv.org/content/10.1101/2020.12.28.424451  	Tian et al. (2021) | Andreano et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt 		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.351	N501Y	increased affinity for hACE2, "associated with fast growing lineages", within the six key residues in the receptor binding domain (RBD), estimated to cause an increase of between 40% and 70% in transmissibility, Experimentally, ACE2 binding affinity increased 0.24 fold, Calculated disassociation constant for this variant is nearly four fold lower than wild type (455 pM vs 1600pM); contributor to convalescent plasma escape (Pokay) "#Among the first selected variants in an in vitro evolution experiment for ACE2 binding. #Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392 #Experimentally, ACE2 binding affinity increased 0.06 fold #Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012", "# This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity # Andreano et al. (2020)https://www.biorxiv.org/content/10.1101/2020.12.28.424451", "# Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage) # Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831 # Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages # Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages # Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf # The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110). # Barnes et al. (2020) https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub # Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody # Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody # Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007", "# Ablates binding by class 2 mAbs such as C144 that do not directly interfere with ACE2 binding,  # BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  # show pronounced increase in binding to the variant.  # Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2" (Pokay)	ACE2 receptor binding affinity increase | Convalescent plasma escape | Homoplasy | Monoclonal antibody serial passage escape | Vaccine neutralization efficacy | Variant linear antibody epitope effect	Experimentally, ACE2 binding affinity increased 0.24 fold |  Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus. | Variant within the six key residues in the receptor binding domain (RBD). | In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613. | In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed. | Decrease in potency was  observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	https://doi.org/10.1016/j.cell.2020.08.012 | https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2 | https://www.mdpi.com/2076-0817/10/2/184/htm | https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2 | https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  | https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1 	Starr et al. (2020) | Shen et al. (2021) | Flores-Alanis et al. (2021) | Wang et al. (2021) | Wang et al. (2021)  | Rees-Spear et al. (2021) 	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_homoplasy.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_vaccine_neutralization_efficacy.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt 		complete for now: Added one function for each category. Have not added  functions that are applicable on a set of mutations, not individual mutation.
B.1.351	A701V								In Pokay, its function so far is only available in combination with other mutations. 
B.1.351	Q57H	Not in Pokay							Not in Pokay
B.1.351	S171L	Not in Pokay							Not in Pokay
B.1.351	P71L	Not in Pokay							Not in Pokay
B.1.351	T205I	Not in Pokay							Not in Pokay
P.1		Not in Pokay							Not in Pokay
P.1		Not in Pokay							Not in Pokay
P.1	S1188L	Not in Pokay							Not in Pokay
P.1	K1795Q	Not in Pokay							Not in Pokay
P.1	3675-3677 SGF	Not in Pokay							Not in Pokay
P.1		Not in Pokay							Not in Pokay
P.1	T4532I	Not in Pokay							Not in Pokay
P.1	E5665D (VIROLOGICAL)	Not in Pokay							Not in Pokay
P.1	S56651 (BIORXIV)	Not in Pokay							Not in Pokay
P.1	L18F								
P.1	T20N								
P.1	P26S								
P.1	D138Y								
P.1	R190S								
P.1	K417T	Same site as the K417N mutation in the B.1.351 lineage. It may help the virus latch on tighter (https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B117). #Experimentally, Spike gene expression increased 0.25 fold (pokay) # Escape mutation against monoclonal antibody LY-CoV016 # Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 # In vitro selection against class 1 antibody C682 # Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Gene expression increase | Monoclonal antibody serial passage escape	Experimentally, Spike gene expression increased 0.25 fold. | Escape mutation against monoclonal antibody LY-CoV016 ; In vitro selection against class 1 antibody C682.	https://doi.org/10.1016/j.cell.2020.08.012 | https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 ; https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2 	Starr et al. (2020)  | Starr et al. (2021) ; Wang et al. (2021) 	https://github.com/nodrogluap/pokay/blob/master/data/S_gene_expression_increase.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt 		complete for now: Have not added  functions that are applicable on a set of mutations, not individual mutation.
P.1	E484K	can "escape several mAbs (including C121, C144, REGN10933, REGN10934) and some convalescent sera", at a key residue in the RBD; "substantially increases the amount of serum antibody needed to prevent infection of cells"; contributor to convalescent plasma escape; "# Ablates binding by class 2 mAbs such as C144 that do not directly interfere with ACE2 binding,  # BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  # show pronounced increase in binding to the variant.  # Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"  (Pokay) #The mutation is in the spike protein and appears to have an impact on the body’s immune response and, possibly, vaccine efficacy. # Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM). # This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity 	ACE2 receptor binding affinity increase | Convalescent plasma escape	Reported moderate increase in affinity compared to wild-type RBD on the cell surface. | Mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity. 	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2  | https://www.biorxiv.org/content/10.1101/2020.12.28.424451  	Tian et al. (2021) | Andreano et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
P.1	N501Y	increased affinity for hACE2, "associated with fast growing lineages", within the six key residues in the receptor binding domain (RBD), estimated to cause an increase of between 40% and 70% in transmissibility, Experimentally, ACE2 binding affinity increased 0.24 fold, Calculated disassociation constant for this variant is nearly four fold lower than wild type (455 pM vs 1600pM) #Variant within the six key residues in the receptor binding domain (RBD), Independently reported in UK, Australia (same origin as UK), and South Africa (independent origin). # In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	ACE2 receptor binding affinity increase | Convalescent plasma escape | Homoplasy | Monoclonal antibody serial passage escape | Vaccine neutralization efficacy | Variant linear antibody epitope effect	Experimentally, ACE2 binding affinity increased 0.24 fold |  Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus. | Variant within the six key residues in the receptor binding domain (RBD). | In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613. | In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed. | Decrease in potency was  observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	https://doi.org/10.1016/j.cell.2020.08.012 | https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2 | https://www.mdpi.com/2076-0817/10/2/184/htm | https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2 | https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  | https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1 	Starr et al. (2020) | Shen et al. (2021) | Flores-Alanis et al. (2021) | Wang et al. (2021) | Wang et al. (2021)  | Rees-Spear et al. (2021) 	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_homoplasy.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_vaccine_neutralization_efficacy.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt 		complete for now: Added one function for each category. Have not added  functions that are applicable on a set of mutations, not individual mutation.
P.1	H655Y	# Associated with reduced susceptibility to neutralizing antibodies  https://www.medrxiv.org/content/10.1101/2021.01.28.21250666v1.full-text 							
P.1	T1027I								
P.1	S253P	Not in Pokay							Not in Pokay
P.1	E92K	Not in Pokay							Not in Pokay
P.1									
P.1	P80R								
P.1	RG203KR								
A.23.1	F157L	Not in Pokay							Not in Pokay
A.23.1	V367F	#Experimentally, ACE2 binding affinity increased 0.07 fold # Widespread amongst mink and humans on one farm, one mink on another farm, potential adaptation. #Experimentally, Spike gene expression increased 0.74 fold # Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding, BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	ACE2 receptor binding affinity increase | Anthropozoonotic events | Gene expression increase | Variant linear antibody epitope effect	Increase in ACE2 binding affinity by 0.07 fold. | Widespread amongst mink and humans on one farm, one mink on another farm, potential adaptation. | Experimentally, Spike gene expression increased by 0.74 fold. | Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding, but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	https://doi.org/10.1016/j.cell.2020.08.012  | http://dx.doi.org/10.1126/science.abe5901 | https://doi.org/10.1016/j.cell.2020.08.012  | https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2 	Starr et al. (2020) | Oude Munnink et al. (2020) | Starr et al. (2020) | Gaebler et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_anthropozoonotic_events.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_gene_expression_increase.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_variant_linear_antibody_epitope_effects.txt 	 increased gene expression: http://purl.obolibrary.org/obo/DDPHENO_0000301 Increase in extent, amount, or degree of gene expression. (Dicty Phenotype Ontology (DDPHENO))  gene expression: http://purl.obolibrary.org/obo/GO_0010467  gene expression: http://purl.obolibrary.org/obo/INO_0000102 	
A.23.1	Q613H	Not in Pokay							Not in Pokay
A.23.1	P681R	Not in Pokay							Not in Pokay
B.1.525	L4715F								
B.1.525	Q52R								
B.1.525	E484K	can "escape several mAbs (including C121, C144, REGN10933, REGN10934) and some convalescent sera", at a key residue in the RBD; "substantially increases the amount of serum antibody needed to prevent infection of cells"; contributor to convalescent plasma escape; "# Ablates binding by class 2 mAbs such as C144 that do not directly interfere with ACE2 binding,  # BUT clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  # show pronounced increase in binding to the variant.  # Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"  (Pokay) #The mutation is in the spike protein and appears to have an impact on the body’s immune response and, possibly, vaccine efficacy. # Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM). # This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity 	ACE2 receptor binding affinity increase | Convalescent plasma escape	Reported moderate increase in affinity compared to wild-type RBD on the cell surface.| Mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity. 	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2  | https://www.biorxiv.org/content/10.1101/2020.12.28.424451  	Tian et al. (2021) | Andreano et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_ACE2_receptor_binding_affinity_increase.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.525	Q677H								
B.1.525	F888L								
B.1.525	L21F	Not in Pokay							Not in Pokay
B.1.525	I82T	Not in Pokay							Not in Pokay
B.1.525	del:11288:9								
B.1.525	del:21765:6								
B.1.525	del:28278:3								
B.1.429	T265I	Not in Pokay							
B.1.429	I4205V	Not in Pokay							
B.1.429	P314L	Not in Pokay							
B.1.429	D1183Y	Not in Pokay							
B.1.429	S13I	# Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429 (pokay).	Transmissibility 	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains.	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	Deng et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_transmissibility.txt	 | viral load: http://purl.obolibrary.org/obo/VIDO_0001331 Quality inhering in a portion of fluid that is the proportion of virions to volume of that portion of fluid (VIDO: The Virus Infectious Disease Ontology) viral load: http://www.ebi.ac.uk/efo/EFO_0010125  A measurement of the quantity of virus in a given volume of body fluid. [ http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern] (EFO: Experimental Factor Ontology)      	complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.429	W152C	# Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429 (pokay). # Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to D614G alone in 293T cells and human airway organoids.	Transmissibility | Trafficking 	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. | Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to D614G alone in 293T cells and human airway organoids. 	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v2  | https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1 	Deng et al. (2021) | Deng et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_transmissibility.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_trafficking.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.429	L452R	# Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429 (pokay). # We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids. # Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered. # Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) # Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 L452R # Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096 # Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007 # Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro. # Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Transmissibility | Trafficking | Convalescent plasma escape | Gene expression increase  | Monoclonal antibody serial passage escape	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. | Pseudoviruses carrying the   L452R mutation demonstrated increased entry compared to D614G alone, with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.| Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered. | Experimentally, Spike gene expression increased 0.32 fold. | Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab). ; Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096 ; Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro. 	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1 | https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1  | https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  |  https://doi.org/10.1016/j.cell.2020.08.012 | https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 ; https://doi.org/10.1016/j.chom.2020.11.007 ; https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2 	Deng et al. (2021) | Deng et al. (2021) | Liu et al. (2021) | Starr et al. (2020) | Starr et al. (2021) ; Greaney et al. (2020) ;  Wang et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_transmissibility.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_trafficking.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_gene_expression_increase.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.429	D614G	# Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry) -(pokay) #Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion. # CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2. #Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2. # Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. 	Trafficking | Virion structure | Viral load	Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry) | Increase infectivity by assembling more functional S protein into the virion ; CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2 ; Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2. | Clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1 | https://www.nature.com/articles/s41467-020-19808-4  ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/ ; https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2 | https://www.nature.com/articles/s41586-020-2895-3 	Barrett et al. (2021) | Zhang et al. (2020) ; Yurkovetskiy et al. (2020) ; Weissman et al. (2020) | Plante et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_trafficking.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt   | https://github.com/nodrogluap/pokay/blob/master/data/S_viral_load.txt 	in ontology we have  'structural constituent of virion': The action of a molecule that contributes to the structural integrity of a virion. 'virion': Virus that is in its assembled state consisting of genomic material (DNA or RNA) surrounded by coating molecules. virion assembly: A late phase of the viral life cycle during which all the components necessary for the formation of a mature virion collect at a particular site in the cell and the basic structure of the virus particle is formed.	complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.429	Q57H	Not in Pokay							Not in Pokay
B.1.429	T205I	Not in Pokay							Not in Pokay
B.1.427	D614G	# Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry) -(pokay) #Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion. # CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2. #Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2. # Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. 	Trafficking | Virion structure | Viral load	Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry) | Increase infectivity by assembling more functional S protein into the virion ; CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2 ; Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2. | Clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1 | https://www.nature.com/articles/s41467-020-19808-4  ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/ ; https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2 | https://www.nature.com/articles/s41586-020-2895-3 	Barrett et al. (2021) | Zhang et al. (2020) ; Yurkovetskiy et al. (2020) ; Weissman et al. (2020) | Plante et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_trafficking.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt   | https://github.com/nodrogluap/pokay/blob/master/data/S_viral_load.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.427	T265I	Not in Pokay							Not in Pokay
B.1.427	D1183Y	Not in Pokay							Not in Pokay
B.1.427	T205I								
B.1.427	L452R	# Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429 (pokay). # We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids. # Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered. # Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) # Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 L452R # Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096 # Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007 # Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro. # Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Transmissibility | Trafficking | Convalescent plasma escape | Gene expression increase  | Monoclonal antibody serial passage escape	Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. | Pseudoviruses carrying the   L452R mutation demonstrated increased entry compared to D614G alone, with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.| Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered. | Experimentally, Spike gene expression increased 0.32 fold. | Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab). ; Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096 ; Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro. 	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1 | https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1  | https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  |  https://doi.org/10.1016/j.cell.2020.08.012 | https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1 ; https://doi.org/10.1016/j.chom.2020.11.007 ; https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2 	Deng et al. (2021) | Deng et al. (2021) | Liu et al. (2021) | Starr et al. (2020) | Starr et al. (2021) ; Greaney et al. (2020) ;  Wang et al. (2021)	https://github.com/nodrogluap/pokay/blob/master/data/S_transmissibility.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_trafficking.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_convalescent_plasma_escape.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_gene_expression_increase.txt  | https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_monoclonal_antibody_serial_passage_escape.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.427	S3158T	Not in Pokay							
B.1.427	P976L	Not in Pokay							
B.1.427	Q57H	Not in Pokay							
B.1.526	Q1011H	Not in Pokay							
B.1.526	D253G								
B.1.526	D614G	# Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry) -(pokay) #Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion. # CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2. #Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2. # Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. 	Trafficking | Virion structure | Viral load	Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry) | Increase infectivity by assembling more functional S protein into the virion ; CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2 ; Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2. | Clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1 | https://www.nature.com/articles/s41467-020-19808-4  ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/ ; https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2 | https://www.nature.com/articles/s41586-020-2895-3 	Barrett et al. (2021) | Zhang et al. (2020) ; Yurkovetskiy et al. (2020) ; Weissman et al. (2020) | Plante et al. (2020)	https://github.com/nodrogluap/pokay/blob/master/data/S_trafficking.txt | https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt ; https://github.com/nodrogluap/pokay/blob/master/data/S_virion_structure.txt   | https://github.com/nodrogluap/pokay/blob/master/data/S_viral_load.txt 		complete for now: Have not added functions  (if any) that are applicable on a set of mutations, not individual mutation.
B.1.526	P314L	Not in Pokay							
B.1.526	L3201P	Not in Pokay							
B.1.526	T265I	Not in Pokay							
B.1.526	Q57H	Not in Pokay							
B.1.526	T95I								
B.1.526	P42L	Not in Pokay							
B.1.526	T11I	Not in Pokay							